Treatment of Atrial Fibrillation: Dronedarone -- Differences Between Amiodaron and Other Antiarrhyth

March 14, Sunday 4:30 PM to 6:00 PM
An ATHENA trial showed that after a 30-month follow up of more than 4,000 atrial fibrillation (AF) and atrial flutter patients, cardiovascular hospitalizations and death occurred 24 percent less in patients administered dronedarone than in those administered a placebo. A post-hoc analysis of the ATHENA trial also showed that those on the drug had a reduction in stroke.

While amiodarone has been on the U.S. market since the mid-1980s, dronedarone is a new-comer. How do physicians gauge the difference between drugs that have been around for decades with newer-generation therapies? In this session. Dr. Peter Smith from Marshfield, Wis., will present anti-arrhythmic case presentations and a panel of distinguished physicians in the EP field will discuss the ramifications.

Location: Room B402

Speaker Information:
Peter N. Smith, MD, Marshfield, Wis.
Melanie T. Gura, MD, Hudson, Ohio
Joseph S. Alpert, MD, Tucson, Ariz.
Sangeeta B. Shah, MD, Harvey, La.

Subscribe to Cardiovascular Business News

Subscribe to Cardiovascular Business News

Subscribe to Cardiovascular Business News